Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Boehringer Ingelheim
Sort By
Newest First
1 / 2
1 / 2
Investment
Boehringer Ingelheim Invests Nearly $50 Million to Expand Plant in Puerto Rico
Boehringer Ingelheim
PR-M11-19-NI-014
Nov 15, 2019
Clinical Data
New Data Reinforces Benefits of Spiolto® Respimat® in Improving Patient Outcomes
Boehringer Ingelheim
PR-M10-19-NI-001
Oct 01, 2019
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Disease
Boehringer Ingelheim
PR-M09-19-NI-050
Sep 23, 2019
Virtual Research
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
Boehringer Ingelheim
PR-M08-19-NI-041-2259
Aug 15, 2019
M&A
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
Boehringer Ingelheim
PA2368
Jul 17, 2019
Investment
Boehringer Ingelheim Investing in Mexico
Nice Insight
PAO-M05-19-NI-033
May 31, 2019
Legal
AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
AbbVie
PR-M05-19-NI-056
May 20, 2019
Real World Data
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors
Eli Lilly and Company
PR-M11-18-NI-032
Nov 09, 2018
Partnership
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Announce New Partnership
Boehringer Ingelheim
PR-M08-18-NI-049
Aug 13, 2018
Insulin
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
Boehringer Ingelheim
PR-M06-18-NI-084
Jun 26, 2018
Discovery Platform
Biomax Informatics Software Licensed by Global Pharma Company, Boehringer Ingelheim, to Build a Target Discovery Knowledge Platform
Biomax Informatics
PR-M05-18-NI-038
May 10, 2018
Drug Development
Praxbind®, Specific Reversal Agent for Pradaxa®, Now Available in 3,200 Hospitals Nationwide
Boehringer Ingelheim
PR-M05-18-NI-034
May 09, 2018
Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries
Boehringer Ingelheim
PA4352
Apr 30, 2018
FDA Approval
FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa
Boehringer Ingelheim
PR-M04-18-NI-74
Apr 20, 2018
Collaboration
Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford
Boehringer Ingelheim
PR-M04-18-NI-64
Apr 18, 2018
Animal Health
LEUKOCARE and Boehringer Ingelheim Enter into a Long-Term Agreement in the Field of Animal Health
Boehringer Ingelheim
PR-M04-18-NI-53
Apr 16, 2018
Immuno-Oncology
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership
Boehringer Ingelheim
PR-M04-18-NI-030
Apr 10, 2018
Clinical Trials
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine
Boehringer Ingelheim
PR-M04-18-NI-001
Apr 02, 2018
Awareness
Boehringer Ingelheim and Minor League Baseball Team Up to Raise Awareness of Rare Lung Disease – IPF
Boehringer Ingelheim Pharmaceuticals, Inc.
PR-M03-18-NI-106-4484
Mar 29, 2018
Clinical Trial Data
Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis
Boehringer Ingelheim
PR-M03-18-NI-086
Mar 23, 2018